Pre-MAF technical information

History of Gc globulin/GcMAF pre-MAF research

1991: Professor Nobuto Yamamoto of Temple University discovers Gc globulin

Research on FcR-mediated activation of phagocytic activity in macrophages revealed the involvement of serum factors, and serum factors with lower molecular weights than albumin contained in the α2-globulin fraction were found to be involved through an assessment using electrophoretic fractionation, 50% saturated ammonium sulfate fractionation, and Sephadex G-100 fractionation. Gc globulin was discovered through immunoadsorption using rabbit antiserum, and GcMAF was subsequently discovered and defined through treatment with various specific lectins and enzymes.

Source: Nobuto Yamamoto, Sadamu Homma, Irving Millman, J. Immunol., 147, 273-280, 1991.
Nobuto Yamamoto, Sadamu Homma., Proc. Natl. Acad. Sci. USA, 88, 8539-8543, 1991.

1992: Research on GcMAF begins in the laboratory of Professor Hitoshi Hori (currently an advisor to our company) at Tokushima University

2011: Collaborative research with Tokyo University of Science begins
First journal article on pre-MAF published
Effect of the Gc-derived Macrophage-activating Factor Precursor (preGcMAF) on Phagocytic Activation of Mouse Peritoneal Macrophages. Anticancer Res., 31, 2489-2492, 2011

2012: Second journal article on pre-MAF published
β-Galactosidase Treatment Is a Common First-stage Modification of the Three Major Subtypes of Gc Protein to GcMAF. Anticancer Res.,32, 2359-2364, 2012

2013: Third journal article on pre-MAF published
Antitumor Effect of Degalactosylated Gc-globulin on Orthotopic Grafted Lung Cancer in Mice. Anticancer Res., 33, 2911-2916, 2013

December 2014: Dedicated research building for pre-MAF production/research established

2015: Patent for the synthesis method of pre-MAF specific adsorption resins obtained (Patent No. 5701587)
Patent for the pre-MAF production method obtained (Patent No. 5860401)

2017: Collaborative research with the Jikei University School of Medicine begins

January 2021: Collaborative research on administration to humans for cancer treatment at the clinic begins

April 2022: Collaborative research on administration to humans for aging care at the clinic begins